ORTHOPEDIATRICS CEO granted 119,140 shares

Bailey David R reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Bailey David R reported acquisition or exercise transactions in this Form 4 filing.

ORTHOPEDIATRICS CORP President and CEO David R. Bailey received a grant of 119,140 shares of Common Stock on June 9, 2026. The award was reported at a price of $0.00 per share, indicating a stock-based compensation grant rather than an open-market purchase.

Following this grant, Bailey directly holds 417,160 shares of the company’s Common Stock. The holdings include restricted stock awards totaling 307,031 shares, which typically vest over time and are subject to continued service or performance conditions.

Insider Trade Summary

Grant/Award: 119,140 shares

Grant/Award 1 txn

Insider Bailey David R

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	119,140	$0.00	$0.00

Holdings After Transaction: Common Stock — 417,160 shares (Direct)

Footnotes (1)

1. F1. Includes restricted stock awards totaling 307,031 shares.

Key Figures

Stock grant size: 119,140 shares Grant price: $0.00 per share Post-grant holdings: 417,160 shares +1 more

4 metrics

Stock grant size 119,140 shares Common Stock awarded on June 9, 2026

Grant price $0.00 per share Reported value for the 119,140-share award

Post-grant holdings 417,160 shares Total Common Stock directly held after the transaction

Restricted stock awards 307,031 shares Restricted stock included in Bailey’s holdings

Key Terms

restricted stock awards, Common Stock, grant, award, or other acquisition

3 terms

restricted stock awards financial

"Includes restricted stock awards totaling 307,031 shares."

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ORTHOPEDIATRICS (KIDS) report for David R. Bailey?

ORTHOPEDIATRICS reported that President and CEO David R. Bailey received a grant of 119,140 shares of Common Stock. The award was recorded at $0.00 per share, indicating stock-based compensation rather than an open-market purchase.

How many ORTHOPEDIATRICS (KIDS) shares does David R. Bailey now hold?

After the June 9, 2026 grant, David R. Bailey directly holds 417,160 shares of ORTHOPEDIATRICS Common Stock. This total includes previously held shares as well as the newly granted 119,140-share award reported in the Form 4.

Were the new ORTHOPEDIATRICS (KIDS) shares bought on the market by David R. Bailey?

No, the 119,140 shares were reported with a price of $0.00 per share, reflecting a grant of stock-based compensation. This differs from an open-market purchase where the insider pays cash to buy shares at prevailing market prices.

How many restricted ORTHOPEDIATRICS (KIDS) shares does David R. Bailey hold?

The filing notes that David R. Bailey’s holdings include restricted stock awards totaling 307,031 shares. Restricted shares typically vest over time and may be subject to continued employment or performance conditions before they become fully transferable.

What does transaction code "A" mean in the ORTHOPEDIATRICS (KIDS) Form 4?

Transaction code “A” on the Form 4 indicates a grant, award, or other acquisition of securities. In this case, it reflects the award of 119,140 shares of ORTHOPEDIATRICS Common Stock to President and CEO David R. Bailey as stock-based compensation.

Is the ORTHOPEDIATRICS (KIDS) CEO’s share increase from a compensation grant or a sale-related event?

The CEO’s share increase comes from a compensation grant, not from a sale-related event. The Form 4 shows an acquisition of 119,140 shares at $0.00 per share, consistent with an equity award rather than market buying or selling activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 09:49 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bailey David R

(Last) (First) (Middle)

C/O ORTHOPEDIATRICS CORP.

2850 FRONTIER DRIVE

(Street)

WARSAW INDIANA 46582

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ORTHOPEDIATRICS CORP [ KIDS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		119,140	A	$0	417,160(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes restricted stock awards totaling 307,031 shares.

Remarks:

	/s/ Daniel J. Gerritzen, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)